Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kansas Medical Center
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients undergoing wide resection of a malignant bony tumor of the lower extremity with endoprosthetic reconstruction.

• Patients undergoing a resection of soft tissue sarcoma measuring > 5cm.

Exclusion Criteria:

• Patients undergoing revision endoprosthetic reconstruction

• Patients with known coagulopathy

• Known history of DVT or embolic disease

• Benign tumors

• Patients with allergy to TXA

• Those refusing blood products

• Those concurrently on anti-coagulant therapy

• Pregnant and/or nursing women

• Vulnerable populations as defined by the KUMC IRB